Neuro-Oncology: The Podcast
by Neuro-Oncology
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 9 chart positions in 9 markets.
By chart position
- 🇩🇪DE · Medicine#1195K to 30K
- 🇧🇷BR · Medicine#1591K to 10K
- 🇦🇪AE · Medicine#1930K to 100K
- 🇵🇹PT · Medicine#2510K to 30K
- 🇭🇺HU · Medicine#4710K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
21K to 74K🎙 Daily cadence·126 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
70K to 246K🇦🇪41%🇩🇪12%🇵🇹12%+6 more - Active Followers
Loyal subscribers who consistently listen
21K to 74K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 24 epsHosts
Recent guests
Recent episodes
SNOBound: Career Advice with Dr. Justin Lathia
Jul 10, 2026
17m 33s
Author Interviews: cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas
Jul 6, 2026
28m 12s
A Conversation on Career Journeys with SNO's Young Investigator Committee Chairs
Jun 26, 2026
29m 22s
Neuro-onc Narratives: Two Insiders, One Diagnosis: A Neurosurgeon and Healthcare Leader on Living with GBM
Jun 19, 2026
39m 07s
Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single-institution experience
Jun 15, 2026
16m 12s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/10/26 | neuro-oncologycareer advice+2 | Dr. Justin Lathia | Neuro-Oncology | — | neuro-oncologycareer advice+3 | — | 17m 33s | ||
| 7/6/26 | Neuro-oncologyIDH-mutant Gliomas+3 | Daniel Brat | cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas | — | Neuro-oncologyIDH-mutant Gliomas+3 | — | 28m 12s | ||
| 6/26/26 | career journeysearly-career trainees+3 | Jasia MahdiJacob Young+1 | SNOYoung Investigator Committee | — | career adviceneuro-oncology+3 | — | 29m 22s | ||
| 6/19/26 | glioblastomahealthcare+3 | Shannon Thomas, RN, MSNShannon Thomas | Eden Medical Center | Castro Valley, CA | glioblastomaneurosurgeon+3 | — | 39m 07s | ||
| 6/15/26 | gliomaIDH1 mutation+3 | Sofia RaelUgur Sener | Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single institution experience | — | IvosidenibIDH1-mutant+4 | — | 16m 12s | ||
| 6/1/26 | glioblastomaAI model+3 | Santiago Cepeda | Prospective biopsy-controlled validation of an AI model for predicting glioblastoma infiltration: Results from the SupraGlio trial | — | glioblastomaAI+5 | — | 29m 19s | ||
| 5/30/26 | clinical trialpersonalized medicine+3 | Shahad Abdulsahib | GNOS-PV01UT Health San Antonio+1 | — | GT-20MGMT unmethylated glioblastoma+3 | — | 3m 19s | ||
| 5/25/26 | neuro-oncologybiomarker-guided therapies+3 | Prof. Dr. Ghazaleh Tabatabai | Hertie Institute for Clinical Brain ResearchUniversity Hospital Tübingen+1 | — | neuro-oncologybiomarkers+3 | — | 16m 23s | ||
| 5/18/26 | Neurosurgeryinterview+3 | Sarah MenachoBen Shofty | Neurosurgery | — | Neurosurgeryinterview+3 | — | 34m 26s | ||
| 5/15/26 | wellnessburnout+3 | Nick Gonzalez CastroRaj Mukherjee | SNO Wellness Committee | — | wellnessburnout+3 | — | 24m 37s | ||
| 5/11/26 | clinical trialfocused ultrasound+3 | — | temozolomideUT Health San Antonio+1 | high-grade glioma | BT008NA trialfocused ultrasound+4 | — | 3m 56s | ||
| 5/8/26 | neuropathologyneuro-oncology+3 | Dr. Ryan Cecchi | — | — | neuropathologyneuro-oncology+5 | — | 19m 35s | ||
| 5/4/26 | chemotherapyIDHmt+4 | David Schiff | CATNON Conclusion: Closure on concurrent chemotherapy in IDHmt Grade 3 Astrocytoma | — | chemotherapyIDHmt+5 | — | 27m 33s | ||
| 5/1/26 | neuro-oncologymedical advancements+3 | Dr. Fabio Iwamoto | Stanford | — | neuro-oncologyDr. Fabio Iwamoto+3 | — | 16m 48s | ||
| 4/27/26 | career developmentneuro-oncology+1 | — | SNO | — | career developmentneuro-oncology+3 | — | 3m 11s | ||
| 4/24/26 | brain tumorart therapy+3 | Caroline Catlin | The New York TimesLongreads+3 | — | brain tumorart+5 | — | 38m 06s | ||
| 4/20/26 | IDH-mutant astrocytomaDNA copy number patterns+4 | Bob Jenkins | DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma | — | IDH-mutant astrocytomaDNA copy number+4 | — | 35m 16s | ||
| 4/17/26 | adolescent and young adultneuro-oncology+2 | Dr. Mary Jane (MJ) Lim-FatDr. Kee Kiat (Aaron) Yeo | Neuro-Oncology | — | AYAneuro-oncology+4 | — | 31m 43s | ||
| 4/13/26 | CAR T cellsglioblastoma+3 | Shahad Abdulsahib | bivalent EGFR/IL13Rα2 CAR T cellsNature Medicine | recurrent glioblastoma | CAR T cellsglioblastoma+5 | — | 2m 29s | ||
| 4/10/26 | career adviceradiation oncology+3 | Dr. Brooke Braman | Radiation Oncology | — | radiation oncologycareer advice+3 | — | 23m 04s | ||
| 4/6/26 | clinical trialsCNS tumors+3 | Dr. Margit K. MikkelsenDr. Daniel C. Moreira | St. Jude Children's Research HospitalNeuro-Oncology Pediatrics+1 | — | clinical trialsCNS tumors+5 | — | 20m 41s | ||
| 3/23/26 | DIPGCAR T cells+3 | Shahad Abdulsahib | Nature Medicineintracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma | — | DIPGB7-H3+4 | — | 2m 52s | ||
| 3/20/26 | patient well-beingneuro-oncology+3 | Dr. Ashlee LoughanDr. Sarah Brahn | Neuro-Oncology | — | neuro-oncologypatient advocacy+3 | — | 42m 50s | ||
| 3/16/26 | optic pathway low-grade gliomavisual morbidity+3 | Dr. Stefania PicarielloDr. Enrico Opocher | Visual morbidity, long-term outcome, and prognostic factors in infants and young children with optic pathway low-grade glioma | — | optic pathway gliomavisual morbidity+3 | — | 17m 33s |
Showing 24 of 24
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Nature Podcast
Springer Nature Limited
Neurology® Podcast
American Academy of Neurology
Huberman Lab
Scicomm Media
Practical Neurology Podcast
BMJ Group
Continuum Audio
American Academy of Neurology
Congress of Neurological Surgeons Podcasts
Congress of Neurological Surgeons
All-In with Chamath, Jason, Sacks & Friedberg
All-In Podcast, LLC
Chart history for Neuro-Oncology: The Podcast
Peaked at #19 in AE, currently #19 in AE.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| AE | — | #19 | #19 | — |
| PT | — | #25 | #25 | — |
| HU | — | #47 | #47 | — |
| PH | — | #47 | #47 | — |
| CO | — | #51 | #51 | — |
| RO | — | #104 | #104 | — |
| Germany | — | #119 | #119 | — |
| IL | — | #156 | #156 | — |
| Brazil | — | #159 | #159 | — |
| AE | — | #186 | #186 | — |
Chart Positions
10 placements across 9 markets.
Chart Positions
10 placements across 9 markets.